Non-Hodgkin Lymphoma | Specialty

Combination Therapy in Large Cell Lymphomas

January 22nd 2014

Brentuximab Vedotin in Diffuse Large B-cell Lymphoma

January 22nd 2014

PI3K Inhibition in Hematologic Malignancies

January 22nd 2014

Bcl-2 Inhibition With ABT-199 in CLL, Lymphomas

January 22nd 2014

Combining and Sequencing New Agents in CLL

January 22nd 2014

Efficacy and Future Role of Ibrutinib in CLL and MCL

January 22nd 2014

Surrogate Endpoints for New Drug Discovery in ALL

January 22nd 2014

Emerging Strategies in the Treatment of ALL

January 22nd 2014

Novel Therapies for Patients Ph-Negative ALL

January 22nd 2014

Introduction: Treating ALL in Adult Patients

January 22nd 2014

Anti-PD-1 Antibody Pidilizumab Shows Promise in Diffuse Large B-Cell Lymphoma

January 17th 2014

The anti-PD-1 monoclonal antibody pidilizumab showed promising clinical activity and was safely administered to patients with diffuse large B-cell lymphoma after autologous hematopoietic stem-cell transplantation.

Brentuximab Vedotin Shows Activity in B-Cell Lymphomas

December 12th 2013

Brentuximab vedotin has demonstrated antitumor activity in the setting of relapsed or refractory DLBCL across a broad range of CD30 expression, including low or undetectable CD30 expression.

Dr. Seymour on the Efficacy of ABT-199 in High-Risk CLL

December 8th 2013

John F. Seymour, MBBS, FRACP, PhD, discusses the efficacy of single-agent ABT-199 (GDC-0199), a novel Bcl-2 inhibitor, in high-risk relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Dr. van den Brink on Adding Ibrutinib to R-CHOP in NHL

December 4th 2013

Marcel R.M. van den Brink, MD, PhD, Head, discusses a trial being presented at the 2013 ASH Annual Meeting, analyzing the addition of ibrutinib to R-CHOP in patients with non-Hodgkin's lymphoma (NHL).

Novel B-Cell Receptor Signaling Inhibitors Show Promise

October 23rd 2013

Drugs targeting B-cell receptor signaling pathways are improving outcomes for patients with B-cell lymphomas; these novel agents include idelalisib and ibrutinib, and are considered a breakthrough for CLL and other B-cell lymphomas.

Ibrutinib Combo Achieves 100% Response Rate in Patients With NHL

August 15th 2013

Adding ibrutinib to standard R-CHOP chemotherapy for non-Hodgkin lymphoma resulted in an objective response rate of 100% in the first-line setting.

Novel PI3K Inhibitor Active in Non-Hodgkin Lymphoma

August 12th 2013

A dual-target PI3 kinase inhibitor known as IPI-145 demonstrated activity in several types of relapsed and refractory non-Hodgkin lymphoma.

Pfizer Discontinues Late-Stage Trial of Inotuzumab Ozogamicin

May 21st 2013

A late-stage trial investigating inotuzumab ozogamicin as a treatment for patients with aggressive non-Hodgkin lymphoma has been halted after interim data showed the agent was unlikely to improve survival.

Follow-Up Scans Do Little to Detect Relapse of Diffuse Large B-Cell Lymphoma

May 15th 2013

Routine follow-up imaging is of limited value in determining whether patients with diffuse large B-cell lymphoma have experienced a relapse of their disease.

Numerous Drug Classes Studied for Use in Follicular Lymphoma

April 9th 2013

Follicular lymphoma is characterized by repeated treatment responses and then relapses, and until more effective frontline therapies become available, researchers will need to generate a growing list of drug choices to keep pace with patients' needs.